Naoki Takada

1.1k citations
59 papers · 774 indexed · h-index 16
Topics
Sarcoma Diagnosis and Treatment (12 papers)Bone Tumor Diagnosis and Treatments (8 papers)Neuroscience and Neuropharmacology Research (7 papers)

In The Last Decade

Naoki Takada

54 papers receiving 757 citations

Peers

Naoki Takada
Comparison fields: 5 of 119
  • Molecular Biology 228
  • Cellular and Molecular Neuroscience 173
  • Neurology 115
  • Cognitive Neuroscience 104
  • Physiology 97
Replace Frédéric Lallemand with:
Frédéric Lallemand Belgium
Xiaowen Li China
Yaoming Chen China
Snehajyoti Chatterjee India
Lina Ji China
Eun-Jeong Yang South Korea
Marzia Lecchi Italy
Hyun-Joo Park South Korea
Rossella Canese Italy
Ruiyun Peng China
Naoki Takada relative to Frédéric Lallemand Belgium Frédéric Lallemand's profile →
Citations per field
00.5×1.5×
Frédéric Lallemand · 1×
Citations per year

Countries citing papers authored by Naoki Takada

Since Specialization
Citations

This map shows the geographic impact of Naoki Takada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Naoki Takada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Naoki Takada more than expected).

Fields of papers citing papers by Naoki Takada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Naoki Takada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Naoki Takada. The network helps show where Naoki Takada may publish in the future.

Co-authorship network of co-authors of Naoki Takada

This figure shows the co-authorship network connecting the top 25 collaborators of Naoki Takada. A scholar is included among the top collaborators of Naoki Takada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Naoki Takada. Naoki Takada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 1
3 0
4 1
5 0
6 1
7 0
8 29
9 14
10 1
11 14
12 4
13 6
14 4
15 35
16 6
17 10
18 64
19 1
20 16

About Naoki Takada

Naoki Takada is a scholar working on Neurology, Rheumatology and Toxicology, having authored 59 papers that have together received 774 indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (12 papers), Bone Tumor Diagnosis and Treatments (8 papers) and Neuroscience and Neuropharmacology Research (7 papers). The work is most often cited by research in Neurology (115 citations), Biological Psychiatry (34 citations) and Cellular and Molecular Neuroscience (173 citations). Naoki Takada has collaborated with scholars based in Japan, United States and Germany. Frequent co-authors include Yukio Komatsu, Guiqin Zhang, Tetsuya Mizuno, Hideyuki Takeuchi, Shijie Jin, Jun Kawanokuchi, Jinyan Wang, Akio Suzumura, Yoshifumi Sonobe and Shinobu Itoh. Their work appears in journals such as Science, Journal of the American Chemical Society and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026